Effect of Semaglutide on Cardiac Structure and Function in Patients with Obesity-Related Heart Failure
About this episode
In the October 22, 2024 issue of JACC, a podcast explores the promising benefits of semaglutide, a glucagon-like peptide receptor agonist, in treating obesity-related heart failure. The episode discusses key findings from original research, highlighting how semaglutide improves cardiac structure and function, attenuates adverse remodeling, and showcases the dual mechanisms—both weight-related and independent—behind these effects.
Get every episode summarized
Each time JACC This Week publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from JACC This Week
March 10, 2026: Inside JACC Stats: The State of CV Health in Focus | JACC this W...
JACC This Week
March 3, 2026: Hypertrophic Cardiomyopathy in Focus—MAPLE-HCM Trial, Myosin Inh...
JACC This Week
February 24, 2026: ACHD Guideline in Focus—From Survival to Stewardship | JACC T...
JACC This Week
February 17, 2026: Women's Cardiovascular Health in Focus: From Inclusion to Red...
JACC This Week